Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Options
Largest borrow rate increases among liquid names » 08:45
02/21/20
02/21
08:45
02/21/20
08:45
RVLV

Revolve Group

$20.46 /

-0.06 (-0.29%)

, APHA

Aphria

$4.26 /

+0.035 (+0.83%)

, DO

Diamond Offshore

$3.67 /

-0.265 (-6.73%)

, WLL

Whiting Petroleum

$2.86 /

-0.145 (-4.83%)

, NVTA

Invitae

$23.81 /

-3.67 (-13.36%)

, PTON

Peloton

$27.01 /

-0.115 (-0.42%)

, CRC

California Resources

$6.51 /

+0.245 (+3.91%)

, INO

Inovio

$3.64 /

-0.17 (-4.46%)

, APPN

Appian

$62.55 /

+0.35 (+0.56%)

, PYX

Pyxus

$4.59 /

+0.33 (+7.76%)

Latest data shows the…

Latest data shows the largest indicative borrow rate increases among liquid option names include: Revolve Group (RVLV) 82.12% +1.78, Aphria (APHA) 43.91% +0.76, Diamond Offshore (DO) 5.68% +0.43, Whiting Petroleum (WLL) 2.12% +0.36, Invitae (NVTA) 1.48% +0.33, Peloton Interactive (PTON) 59.60% +0.33, California Resources (CRC) 10.66% +0.25, Inovio (INO) 8.88% +0.22, Appian Corp (APPN) 1.79% +0.20, and Pyxus International (PYX) 20.34% +0.18.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Thursday
Earnings
Cerus sees FY20 product guidance $89M-$93M  16:05
02/20/20
02/20
16:05
02/20/20
16:05
CERS

Cerus

$5.38 /

+0.18 (+3.46%)

 
ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Cerus reports Q4 EPS (12c), consensus (11c) » 16:04
02/20/20
02/20
16:04
02/20/20
16:04
CERS

Cerus

$5.38 /

+0.18 (+3.46%)

Reports Q4 revenue…

Reports Q4 revenue $26.5M, consensus $25.3M.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Co-Diagnostics completes submission of CE marking registration for COVID-19 test » 14:36
02/20/20
02/20
14:36
02/20/20
14:36
CODX

Co-Diagnostics

$2.78 /

-0.25 (-8.25%)

Co-Diagnostics announced …

Co-Diagnostics announced that its Logix Smart COVID-19 Test technical file has been submitted for registration with the European Community, and that it is expected to be available later this month as an in vitro diagnostic, IVD,for markets that accept a CE marking as valid regulatory approval. Dwight Egan, CEO of Co-Diagnostics, commented, "We are pleased to announce this milestone, which comes after weeks of hard work by our team at Co-Diagnostics to develop a high-performance diagnostic to help prevent the spread of the new strain of coronavirus. Our patented CoPrimer molecules have unique properties that lead to a significant reduction in false positive test results over other polymerase chain reaction technologies, but will also allow for enhanced multiplexing, or identifying multiple targets at once, as we iterate the test to include other strains of coronavirus and mutations of COVID-19."

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Melco Resorts reports Q4 operating revenues $1.45B, consensus $1.46B » 08:05
02/20/20
02/20
08:05
02/20/20
08:05
MLCO

Melco Resorts & Entertainment

$21.68 /

+0.29 (+1.36%)

Net income attributable…

Net income attributable to Melco Resorts & Entertainment Limited for the fourth quarter of 2019 was $68.1 million, or $0.14 per ADS, compared with $126.6 million, or $0.26 per ADS, in the fourth quarter of 2018. The net income attributable to noncontrolling interests during the fourth quarter of 2019 was US$12.7 million and the net income attributable to noncontrolling interests during the fourth quarter of 2018 was $1.7 million, all of which were related to Studio City, City of Dreams Manila and the Cyprus Operations. CEO Lawrence Ho commented, "During the fourth quarter of 2019, despite macro headwinds and the events in Hong Kong, mass gaming operations at all of Melco's integrated resorts have remained robust, which drove group-wide mass table games revenue to expand approximately 12% year-over-year to an all-time-record-high of $850 million. Adjusted Property EBITDA for the fiscal year 2019 has also expanded 14% year-over-year to reach an all-time-record-high of $1,689 million. Melco's portfolio of award-winning integrated resorts, commitment to excellence, and determination to push boundaries have been widely recognized, most recently by the Michelin Guide Hong Kong Macau 2020 with the company remaining as the leading integrated resort operator in the world with the highest number of Michelin-stars. In the recently published 2020 Forbes Travel Guide, Melco was awarded with a record-breaking 107 stars, with Morpheus honored as the world's first and only establishment to attain Forbes Five-Stars across its entire hotel, spa and dining facilities, after a year of its grand opening. The Morpheus Spa also won the Forbes Spa of the Year Award, attaining the highest score among the world's most outstanding spa establishments. Melco continues to prioritize sustainability in its operations. In March 2019, Melco became the first and only hospitality group and integrated resort signatory of the New Plastics Economy Global Commitment, a global initiative to tackle plastic waste and pollution, led by the Ellen MacArthur Foundation in collaboration with the UN Environment. In December 2019, Melco became the first integrated resort and hotel operator in the Macau SAR and Hong Kong SAR to receive ISO 41001:2018 for its efforts in facilities management systems. Melco has also attained ISO 50001:2018 for effective energy management systems and was recognized by global environmental disclosure system CDP as one of China's leading companies in sustainability. Construction on the further expansion of Studio City is progressing. Upon completion, it will offer approximately 900 additional luxury hotel rooms and suites, one of the world's largest indoor water parks, a Cineplex, fine-dining restaurants and state-of-the-art MICE spaces. The Board has, after evaluating the Company's current liquidity position and future expected capital needs, decided to declare another quarterly dividend of US$0.16512 per ADS. Melco remains committed to managing its balance sheet in a prudent manner. As of December 31, 2019, net-debt-to-last-twelve-months-EBITDA remained modest at approximately 2x, enabling us to continue with our regular dividend program, while retaining ample financial flexibility to reinvest in our existing properties and to pursue new development opportunities. Lastly, Japan continues to be a core focus for us. In September 2019, we announced our 'Yokohama First' policy as we focus our Japan team on bringing to Yokohama the best IR the world has ever seen. In December 2019, we submitted our response for the Yokohama RFC. "We believe our focus on the Asian premium segment, a portfolio of high-quality assets, devotion to craftsmanship, dedication to world-class entertainment offerings, market-leading social safeguard systems, established track record of successful partnerships, culture of exceptional guest service, and commitment to employee development puts Melco in a strong position to help Yokohama realize the vision of developing a world-leading IR with a unique, Japanese touch."

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Wednesday
Syndicate
Twist Bioscience 4.64M share Secondary priced at $28.00 » 19:55
02/19/20
02/19
19:55
02/19/20
19:55
TWST

Twist Bioscience

$28.42 /

-2.07 (-6.79%)

The deal size was…

The deal size was increased from $100M to $130M and priced below the last closing price of $28.44. JPMorgan, Cowen and Evercore ISI are acting as joint book running managers for the offering.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20
    Feb
Hot Stocks
Co-Diagnostics announces new orders for vector control tests » 06:35
02/19/20
02/19
06:35
02/19/20
06:35
CODX

Co-Diagnostics

$2.91 /

-0.42 (-12.61%)

Co-Diagnostics announced…

Co-Diagnostics announced that it has received new orders for its vector control tests and equipment from mosquito abatement districts following attendance at several vector control conferences. Co-Diagnostics has recently added new mosquito abatement customers in the Eastern United States as well as the Midwest. Significantly, the company offers tests tailored to all regions of the country, including multiplexed tests that include either eastern equine encephalitis or western equine encephalitis, depending on the abatement district location. As a result of the conference presentation and exhibition, the company received broad domestic and international interest in its products.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Tuesday
Syndicate
Twist Bioscience files to sell $100M in common stock » 16:24
02/18/20
02/18
16:24
02/18/20
16:24
TWST

Twist Bioscience

$30.50 /

+0.3 (+0.99%)

J.P. Morgan Securities…

J.P. Morgan Securities LLC, Cowen and Company, LLC and Evercore Group L.L.C. are acting as joint book-running managers. Robert W. Baird & Co. Incorporated is acting as lead manager.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20
    Feb
Periodicals
Co-Diagnostics test likely ineffective, Seeking Alpha contributor says » 10:10
02/18/20
02/18
10:10
02/18/20
10:10
CODX

Co-Diagnostics

$3.32 /

-0.01 (-0.30%)

Co-Diagnostics' new…

Co-Diagnostics' new coronavirus test is likely ineffective, according to Seeking Alpha contributor White Diamond Research. According to White Diamond, there is nowhere for Co-Diagnostics to test the coronavirus COVID-19 strain except China or a government lab in the U.S., adding that there "isn't very much substance behind the company" and that its technology isn't useful compared to the competition. The firm also says that the Zika test is Co-Diagnostics' "real" product, not the coronavirus test. Reference Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Options
Unusually active option classes on open February 18th » 09:40
02/18/20
02/18
09:40
02/18/20
09:40
BEN

Franklin Resources

$24.37 /

+ (+0.00%)

, PVG

Pretium Resources

$7.42 /

+ (+0.00%)

, INO

Inovio

$4.16 /

+ (+0.00%)

, WWE

WWE

$44.94 /

+ (+0.00%)

, ABT

Abbott

$89.69 /

+ (+0.00%)

, WMT

Walmart

$117.89 /

+ (+0.00%)

, UNG

United States Natural Gas Fund

$14.34 /

+ (+0.00%)

, GOLD

Barrick Gold

$19.73 /

+ (+0.00%)

, GDXJ

VanEck Vectors Junior Gold Miners

$40.97 /

+ (+0.00%)

Unusual total active…

Unusual total active option classes on open include: Franklin Resources (BEN), Pretium Resources (PVG), Inovio (INO), WWE (WWE), Abbott (ABT), Wal-Mart (WMT), Berkshire Hathaway (BRK/B), U.S. Natural Gas Fund (UNG), Barrick Gold (GOLD), and GDXJ (GDXJ).

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.